Strategies to treat vulnerable plaques
EAS Academy, David Erlinge, 217777
Novel therapeutic approaches using antisense inhibition (TBD)
EAS Academy, Joseph L. Witztum, 217776
Lessons from genetics: risk-score and novel candidates
EAS Academy, Brian A. Ference, 217775
Atherothrombosis; from pathogenesis to treatment
EAS Academy, Steffen Massberg, 217774
NOVEL ROLE OF A TRIGLYCERIDE-SYNTHESIZING ENZYME: DGAT1 AT THE CROSSROAD BETWEEN TRIGLYCERIDE AND CHOLESTEROL METABOLISM
EAS Academy, Vinay Sachdev, 217771
GENETIC REGULATION OF HDL CHOLESTEROL LEVELS DURING SEPSIS
EAS Academy, Liam Brunham, 217769
Lipid Signaling pathways in physiology and disease
EAS Academy, Peter Tontonoz, 217768
The role of bile acids in cholesterol homeostasis
EAS Academy, Albert K. Groen, 217767
Panel Discussion
EAS Academy, Session Speakers, 218366
The ideal patient for PCSK9
EAS Academy, J.Wouter Jukema, 217755
Combination therapy: When and how
EAS Academy, Michel Farnier, 217764
How to control atherogenic dyslipidaemia
EAS Academy, Henry Ginsberg, 217763
Panel Discussion
EAS Academy, Session Speakers, 218372
PCSK9 Inhibition in high risk patients
EAS Academy, Gabriel Steg, 217754
Lipids, inflammation and CV risk
EAS Academy, Erik Stroes, 217753
New targets for controlling dyslipidaemias and atherosclerosis: chair
EAS Academy, Paolo Parini, 217757
Silencing genes, new targets
EAS Academy, Sotirios Tsimikas, 217758
APO B CONTAINING LIPOPROTEINS A BETTER TARGET FOR CV RISK REDUCTION?
EAS Academy, Brian A. Ference, 217762
Dysregulation of hepatic and lipoprotein metabolism in the atherogenic dyslipidemia
EAS Academy, Marja-Riitta Taskinen, 217750
Reality check: Can we get to goals in guidelines?
EAS Academy, Ulrich Laufs, 217747
Will inhibiting thrombus formation prevent acute coronary syndromes?
EAS Academy, Stephan Gielen, 217746
Will aggressive LDL reduction prevent atherosclerosis?
EAS Academy, Alberico Luigi Catapano, 217744
RNA editing controls atherosclerosis
EAS Academy, Stefanie Dimmeler, 217741
Shifting concepts in the description of the “vulnerable plaque”
EAS Academy, Gerard Pasterkamp, 217740
Defective Inflammation Resolution in Atherosclerosis: Mechanisms and Therapeutic Opportunities
EAS Academy, Ira Tabas, 217739
Neoatherosclerosis from a pathologist's point of view
EAS Academy, Renu Virmani, 217738
A PLASMA CIRCULATING MIRNAS PROFILE PREDICTS TYPE 2 DIABETES MELLITUS AND PREDIABETES: FROM THE CORDIOPREV STUDY
EAS Academy, Antonio Camargo, 217735
DEVELOPMENT OF ANTISENSE DRUG TARGETING PCSK9
EAS Academy, Mariko Harada-Shiba, 217734
Are we ready to test the Lp(a) Hypothesis?
EAS Academy, Sotirios Tsimikas, 217732
Nanomedicine as novel atherosclerosis therapy
EAS Academy, Willem J.M. Mulder, 217731
Reducing cholesterol by dietary means
EAS Academy, Eric Bruckert, 217724
DIETARY FAT VS CARBOHYDRATES
EAS Academy, Gabriele Riccardi, 217723
Food4me: the experience
EAS Academy, Michael Gibney, 217722
LDL and apoB-lipoprotein as causative agents in ASCVD
EAS Academy, Chris Packard, 217726
PCSK9 inhibition the clinical evidence
EAS Academy, Peter Sever, 217727
A contemporary approach to dyslipidaemias, PCSK9 inhibition
EAS Academy, Ulf Landmesser, 217728
KEYNOTE LECTURE: Chair
EAS Academy, Petri Kovanen, 217718
Anti-Inflammatory Therapy for Atherosclerosis - Theory and Practice
EAS Academy, Peter Libby, 217719
Genes can hurt you to develop CVD beyond classical risk factors
EAS Academy, Stefano Romeo, 217716
Mining the blood for new cardiometabolic markers
EAS Academy, Robert Gerszten, 217714
High-resolution lipoprotein phenotypes and cardiovascular outcomes
EAS Academy, Samia Mora, 217713
Is there need to revise goals from lipid lowering?
EAS Academy, Ulf Landmesser, 217710
Stress, behavior and cardiovascular disease
EAS Academy, Viola Vaccarino, 217709
Lessons from epidemiology and environmental CVD risk factors
EAS Academy, Salim Yusuf, 217708
Imaging and CVD risk estimation (population studies)
EAS Academy, Valentin Fuster, 217707
Recent evidence for the prevention of atherosclerotic cardiovascular diseases
EAS Academy, Petri Kovanen, 221468
Incremental value of established therapies for dyslipidaemic patients
EAS Academy, Luis Masana Marin, 217811
Lipoprotein Metabolism
EAS Academy, Arnold von Eckardstein, 221467
The Anitschkow Lecture - Genetics of cardiovascular disease: from ugly duckling to beautiful swan
EAS Academy, Anne Tybjaerg-Hansen, 217704
Science versus reality in long term management: Time for a paradigm shift?
EAS Academy, Lale Tokgözoglu, 217702
Optimising therapy through cardiac rehabilitation
EAS Academy, Anselm Gitt, 217701
Patient journey after acute coronary syndromes: can we improve outcomes?: Chair
EAS Academy, Peter Toth, 217699
Hospital management after acute coronary syndromes: Is the risk over ?
EAS Academy, Jose L. Zamorano, 217700
Molecular and biochemical mechanisms involved in the protective effect of Mediterranean diet against atherosclerosis
EAS Academy, Alvaro Hernáez, 217696
Effects of the different dietary fatty acids on health: focus on PUFA n-6. New evidences and controversies
EAS Academy, Andrea Poli, 217695
Why does the diet rich in unsaturated fat protect against cardiovascular disease? Differences between nuts and extra virgin olive oil
EAS Academy, Emilio Ros, 217694
Diet and CVD the epidemiological view
EAS Academy, Salim Yusuf, 217693
The multifaceted aspects of CV prevention: from nutrition to therapy: Chair
EAS Academy, Prof. Alberico L. Catapano, Dr. Alberto Mello e Silva & Dr. Xavier Pinto, 218363
Systemsbiology and cardiovascular disease
EAS Academy, Jörg Menche, 202892
Gut microbiome and atherothrombosis
EAS Academy, Christoph Reinhardt, 202891
Immunothrombosis
EAS Academy, Steffen Massberg, 202888
Monocytes and atherothrombosis
EAS Academy, Johann Wojta, 202889
Clotting factors and atherothrombosis
EAS Academy, Hugo ten Cate, 202886
Humoral immunity and thrombosis
EAS Academy, Christoph Binder, 202890
Antiphospholipid antibodies and thrombosis
EAS Academy, Karl Lackner, 202885
Venous vs. arterial thrombosis
EAS Academy, Cihan Ay, 202881
Tissue Factor
EAS Academy, Nigel Mackman, 202883
Platelets and the vascular wall
EAS Academy, R Koenen, 202882
Mechanisms of plaque rupture and erosion
EAS Academy, Gerard Pasterkamp, 202879
Clinical aspects of atherothrombosis
EAS Academy, Irene Lang, 202878
Will precision medicine help tailor dyslipidemia treatment?
EAS Academy, Alberto Zambon, 200946
Can we refine strategy on HDL by new pharmacological approaches?
EAS Academy, John M. Chapman, 200945
Identification of novel targets in Hypertension and priorities for drug development
EAS Academy, David Rosenbaum, 200944
Nutrigenomics for prevention and treatment of obesity
EAS Academy, Judith Aron-Wisnewsky, 200942
Is there a role for Advanced Atherosclerosis Imaging in targeted cardiovascular therapy?
EAS Academy, Erik Stroes, 200941
Do Novel Biomarkers improve cardiovascular risk stratification?
EAS Academy, Arnold von Eckardstein, 200940
Human Genetics from validation of novel cardiovascular drug targets to molecular diagnosis
EAS Academy, Alain Carrié, 200939
Precision Cardiovascular Medicine: an unmet need or just a fashion?
EAS Academy, Eran Leitersdorf, 200938
News from ESC: the REVEAL trial
EAS Academy, Alberico Luigi Catapano, 193805
News from ESC: the CANTOS trial
EAS Academy, Alberico Luigi Catapano, 196302
News from ESC: an update from the FOURIER study
EAS Academy, Alberico Luigi Catapano, 196303
An introduction to Familial Hypercholesterolaemia for clinicians
EAS Academy, Stefano Romeo, 183923
Treatment of FH: Diet, statin and statin intolerance
EAS Academy, Olov Wiklund, 183924
FH in children
EAS Academy, Albert Wiegman, 183925
Brown adipose tissue: a novel target to comBAT cardiometabolic disease
EAS Academy, Patrick Rensen, 175540
Circadian control of metabolism
EAS Academy, Frank A.J.L. Scheer, 175539
Importance of physical activity in metabolic and cardiovascular health and the influence of obesity and diabetes
EAS Academy, Patrick Schrauwen, 175538
Microbiome and cardiometabolic disease
EAS Academy, Fredrik Bäckhed, 175537
Diet and cardiometabolic health
EAS Academy, Qi Sun, 175536
Large-scale epidemiology assessment of the main determinants of cardiovascular disease
EAS Academy, Sarah Lewington, 175535
Mechanistic insights into innovative therapeutics in lipid lowering in vivo
EAS Academy, Henry Ginsberg, 175534
Temporal versus one-time biomarker measurements
EAS Academy, Lind Lars, 175530
Circulating miRNA for cardiovascular death prediction
EAS Academy, Tanja Zeller, 175529
Typical clinical cases: who may benefit?
EAS Academy, Eric Bruckert, 175527
The clinical evidence: Meta-analysis of the RCT
EAS Academy, Matteo Pirro, 175526
Updates on the guidelines. Which role for nutraceuticals?
EAS Academy, Emilio Ros, 175525
PET/MRI
EAS Academy, Marc Dweck, 175524
CT angiography
EAS Academy, Jason M. Tarkin, 175523
3D ultrasound
EAS Academy, Stephen Nicholls, 175522
Introduction to Detecting plaque burden or vulnerable plaque: Which way should we go?
EAS Academy, Lale Tokgözoglu, 176682
Demystifying the management of hypertriglyceridemia
EAS Academy, Anne Tybjaerg-Hansen, 175521
Hepatic lipid and lipoprotein metabolism
EAS Academy, Marja-Riitta Taskinen, 175520
Regulation of lipid mobilization and lipoprotein secretion by the intestine
EAS Academy, Gary Lewis, 175519
How to treat diabetic dyslipidaemia: Introduction
EAS Academy, Børge Nordestgaard, 175531
How to treat diabetic dyslipidaemia
EAS Academy, Gerald Watts, 175532
How to treat diabetic dyslipidaemia
EAS Academy, Alberto Zambon, 175533
Balancing the fat: lipid droplets and human disease
EAS Academy, Robert Farese, Jr, 175518
How LDL causes inflammation in the artery wall
EAS Academy, Goran Hansson, 175517
HDL-cholesterol and cardiovascular disease: rethinking our approach
EAS Academy, John M. Chapman, 175516
Hypertriglyceridaemia: ApoC-III and ANGPTL3
EAS Academy, Sotirios Tsimikas, 175515
CVD prevention strategies: Discussion
EAS Academy, Session Speakers, 176681
Combination therapy a better way to treat?
EAS Academy, Lale Tokgözoglu, 175514
The value of generic medicines
EAS Academy, Gianni Corrao, 175513
DISCUSSION: What do FOURIER data mean for clinical practice?
EAS Academy, Session Speakers, 175508
Atherosclerosis regression: linking GLAGOV and FOURIER
EAS Academy, Stephen Nicholls, 175507
Why TG-rich lipoproteins/non-HDL-Cholesterol matter when assessing CVD risk?: Discussion
EAS Academy, Session Speakers, 176676
LAL deficiency: Discussion
EAS Academy, Session Speakers, 176678
Enzymatic replacement therapy for lysosomal adic lipase deficiency in adult patients with lysosomal acid lipase deficiency
EAS Academy, Reena Sharma, 175510
Fibrates in the management of AD and CVD risk
EAS Academy, Michal Vrablik, 175512
FOURIER: first outcomes data with a PCSK9 inhibitor
EAS Academy, Terje R Pedersen, 175506
Atherogenic dyslipidemia (AD)
EAS Academy, Alberto Zambon, 175511
LDL is causal to atherosclerosis
EAS Academy, John M. Chapman, 175505
Lysosomal acid lipase deficiency - an underdiagnosed and misdiagnosed cause of dyslipidemia and liver dysfunction
EAS Academy, Maurizio Averna, 175509
Why TG-rich lipoproteins/non-HDL-Cholesterol matter when assessing CVD risk?: Introduction
EAS Academy, Kausik Ray, 176674
Chronic kidney disease
EAS Academy, Alexandros Tselepis, 175502
Familial hypercholesterolaemia
EAS Academy, Kausik Ray, 175500
Primary prevention
EAS Academy, Guy De Backer, 175499
Secondary prevention
EAS Academy, Renata Cifkova, 175498
Prognostics in patients with manifest (acute or chronic) CHD
EAS Academy, Thomas F. Luscher, 175504
Summary and introduction of guidelines
EAS Academy, Alberico Luigi Catapano, 175497
Using naturally randomized genetic evidence to understand heritability of coronary artery disease?
EAS Academy, Brian Ference, 175503
Lowering LDL-C for cardiovascular disease
EAS Academy, Chris Packard, 175496
The case for immune cells: An expanded cardiovascular continuum
EAS Academy, Peter Libby, 175495
Innate immune response drives atherosclerosis
EAS Academy, Mihai Netea, 175494
Role of non-coding RNA for cholesterol homeostasis and atherogenesis
EAS Academy, Kathryn Moore, 175493
Anitschkow Lecture: Hematopoiesis, cholesterol and atherosclerosis
EAS Academy, Alan Tall, 175492
Introduction to Anitschkow prize winner
EAS Academy, Lale Tokgözoglu, 176670
Progress in understanding the role of nutrition in prevention of atherosclerosis: Discussion
EAS Academy, Session Speakers, 176669
The new EAS/ESC Guidelines on diet and lifestyle in cardiovascular prevention
EAS Academy, Gabriele Riccardi, 175491
Nordic and Mediterranean diet patterns from the CVD point of view
EAS Academy, Ursula Schwab, 175490
Life time exposure to LDL-cholesterol is it the key to CVD risk?
EAS Academy, Brian Ference, 175489
Progress in understanding the role of nutrition in prevention of atherosclerosis: Chair
EAS Academy, Jan Borén, 176668
Closing remarks
EAS Academy, Alberico Luigi Catapano, 175488
Clinical Cases Discussion
EAS Academy, Session Speakers, 175487
PCSK9 Inhibition: HIGHLIGHTS FROM RECENT PUBLICATIONS
EAS Academy, Alberico Luigi Catapano, 175486
Combination Therapy with non-Statin lipid lowering therapies
EAS Academy, Stephen Nicholls, 175485
Lipid lowering therapies: statins
EAS Academy, Stephen Nicholls, 175484
HDL, non HDL cholesterol and TG: a role in atherosclerosis?
EAS Academy, Kausik Ray, 175483
Plasma lipoproteins and their role in atherogenesis
EAS Academy, Jan Borén, 175482
Familial hypercholesterolemia detection and treatment and the EAS Initiatives
EAS Academy, Kausik Ray, 175481
Panel discussion
EAS Academy, Session Speakers, 175549
Genetics for the identification of therapeutic targets in dyslipidaemia
EAS Academy, Brian Ference, 175480
CVD: Epidemiology of the risk factors: the central role of LDL cholesterol
EAS Academy, Lale Tokgözoglu, 175479
Lipid guidelines, where we stand?
EAS Academy, Alberico Luigi Catapano, 175478
PCSK9 inhibitor therapy - The cure for atherosclerosis?
EAS Academy, Frederick Raal, 175476
PCSK9: From promise to clinical practice
EAS Academy, Gilles Lambert, 175475
Epidemiology of dyslipidemias focus on the region
EAS Academy, Hung-I Yeh, 175474
Introduction to the course
EAS Academy, Alberico Luigi Catapano, 175473
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The new lipid Guidelines
EAS Academy, Alberico Luigi Catapano, 164450
2016 ESC/EAS Guidelines on the Management of Dyslipidaemias: Part 1
EAS Academy, Lale Tokgözoglu, 164451
PLASMA LIPIDOMIC PROFILES IMPROVE UPON CONVENTIONAL RISK FACTORS TO PREDICT CARDIOVASCULAR EVENTS
EAS Academy, Peter Meikle, 136740
CIRCULATING MICRORNA-122 IS ASSOCIATED WITH INCIDENT METABOLIC SYNDROME AND TYPE-2 DIABETES
EAS Academy, Peter Willeit, 136738
POPULATION APPROACH TO PREVENT CVD
EAS Academy, Eva Bossano Prescott, 136745
LIPIDS: WHAT IS NEW?
EAS Academy, Alberico Luigi Catapano, 136744
CIRCULATING CELLS AND CVD RISK
EAS Academy, Gerard Pasterkamp, 136737
WHAT ARE THE RISK FACTOR TARGETS?
EAS Academy, Ian Graham, 136743
HOW CAN WE IDENTIFY HIGH RISK?
EAS Academy, Ian Graham, 136742
INTRODUCTION: WHAT IS NEW IN THESE GUIDELINES?
EAS Academy, Olov Wiklund, 136741
LESSONS LEARNED FROM EMERGING THERAPIES FOR SEVERE HYPERTRIGLYCERIDEMIA
EAS Academy, Daniel Gaudet, 136735
THE USE OF NOVEL THERAPIES IN ATHEROSCLEROSIS: FROM ANTIBODIES TO NANOTECHNOLOGY
EAS Academy, Erik Stroes, 136734
IN INTEGRATIVE OMICS APPROACH IN HUMAN DISEASE RESEARCH
EAS Academy, Karsten Suhre, 136732
PLEIOTROPIC MOLECULAR TARGETS OF COXIBS REVEALS NOVEL GENOMIC LOCI CONFERRING CORONARY ARTERY DISEASE RISK
EAS Academy, Ingrid Braenne, 136726
WHAT DID WE LEARN FROM Lp(a)? SUMMARY OF THE SATELLITE MEETING
EAS Academy, Gert Kostner, 136731
DEEP SEQUENCING IDENTIFIES DNA METHYLATION DEPENDENT GENES IMPLICATED IN DIABETIC COMPLICATIONS
EAS Academy, Ishant Khurana, 136725
OBESITY AND INFLAMMATORY PROCESSES IN ADIPOSE TISSUE
EAS Academy, Giuseppe Danilo Norata, 136730
LEUKOCYTE TELOMERE LENGTH, GENETICALLY DETERMINED, IS CAUSALLY ASSOCIATED WITH THE PROGRESSION OF CAROTID INTIMA-MEDIA THICKNESS AND INCIDENCE OF CARDIOVASCULAR EVENTS
EAS Academy, Andrea Baragetti, 136724
CHANGE IN BODYMASS INDEX ASSOCIATED WITH LOWEST MORTALITY IN DENMARK
EAS Academy, Shoaib Afzal, 136729
GENETIC DISCOVERIES FOR LIPID GENETIC TRAITS. LESSON LEARNED FROM FAMILIES AND THE GENERAL POPULATION
EAS Academy, Samuli Ripatti, 136722
Low HDL High Triglyceride, Diabetic Dyslipidaemia: Conclusion & Discussion
EAS Academy, Session Speakers, 137121
Lysosomal Aci​d Lipase Deficiency: Conclusion & Discussion
EAS Academy, Session Speakers, 137180
Triglyceride, Remnants and Atherosclerosis
EAS Academy, Børge Nordestgaard, 136721
Lipid Metabolism Abnormalities in LAL-D as a lysosomal storage disease with a focus on specific signs and symptoms
EAS Academy, Maurizio Averna, 137179
Diabetic Dyslipidaemia
EAS Academy, Alberto Zambon, 136720
Lysosomal Aci​d Lipase Deficiency: Chair
EAS Academy, Petri Kovanen, 137177
Lipid Metabolism Abnormalities in general with differential diagnoses including also LAL-D
EAS Academy, Thomas Stulning, 137178
Low HDL High Triglyceride, Diabetic Dyslipidaemia: Chair
EAS Academy, Olov Wiklund, 137181
NAFLD - THE NOVEL TREAT FOR VASCULAR DISEASE
EAS Academy, Marja-Riitta Taskinen, 136719
TRANSLATING NUTRITIONAL SCIENCE INTO CLINICAL PRACTICE
EAS Academy, Vasanti Malik, 136718
DOES THE HEALTHY METABOLICALLY OBESE PHENOTYPE EXIST?
EAS Academy, Luc Van Gaal, 136717
MANAGEMENT OF SUBJECTS AT HIGH CARDIOMETABOLIC RISK - WHERE DO WE FALL?
EAS Academy, Jean-Pierre Despres, 136716
ADIPOSE TISSUE BROWNING AND METABOLIC HEALTH
EAS Academy, Joerg Heeren, 136713
HOW GENES CONTROL CHOLESTEROL
EAS Academy, Michael S. Brown, 136711
SEX-SPECIFIC GENOMIC AND PROTEOMIC REGULATION IN CARDIOVASCULAR DISEASE
EAS Academy, Georgios Kararigas, 136710
SEX-SPECIFIC BIOMARKERS FOR CARDIOVASCULAR DISEASES
EAS Academy, Børge Nordestgaard, 136709
SEX DIFFERENCES IN HEART DISEASE IN CLINICAL PRACTICE
EAS Academy, Eva Bossano Prescott, 136708
PUBLIC HEALTH PERSPECTIVES ON CARDIOVASCULAR CARE FOR MEN AND WOMEN
EAS Academy, Kornelia Kotseva, 136707
Discussion and Conclusion​
EAS Academy, Session Speakers, 137187
Plant Nutraceuticals for the treatment of hypercholesterolemia: The available clinical data
EAS Academy, Eric Bruckert, 137186
To bridge the gap between lifestyle and Pharmacological treatment: do we have an unmet need?
EAS Academy, bernhard paulweber, 137185
Nutraceuticals with​ lipid lowering activity​: who can benefit?​: Chairman’s welcome
EAS Academy, Gerd Assmann, 137182
Role of Nutrition in Disease Pathology: Discussion
EAS Academy, Session Speakers, 137120
NOVEL INTRANASAL ANTI-CETP VACCINE AGAINST THE DEVELOPMENT OF ATHEROSCLEROSIS AND FATTY LIVER DISEASE
EAS Academy, Jaime Mas-Oliva, 136706
SATURATED FAT IN THE DIET: GOOD OR BAD?
EAS Academy, Ingeborg Brouwer, 136701
CURRENT STATUS-PHASE I TRIAL OF CELL-TRANSPLANTATION THERAPY WITH ALLOGENEIC ADIPOSE TISSUE-DERIVED MULTILINEAGE PROGENITOR CELLS IN SEVERE FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS UNDERGOING LDL-APHERESIS
EAS Academy, Masahiro Koseki, 136705
A NOVEL COMBINATORIAL NON-VIRAL VECTOR TO TREAT FAMILIAL HYPERCHOLESTEROLAEMIA (FH)
EAS Academy, Alastair Kerr, 136704
ROLE OF SODIUM IN ATHEROSCLEROSIS
EAS Academy, Jens M. Titze, 136700
Debate on Statin Associated Muscle Symptoms (SAMS) - A Problem for Clinicians or a Problem with Clinicians?: Discussion
EAS Academy, Session Speakers, 137119
COMPARATIVE EFFECTS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITION, STATIN AND EZETIMIBE THERAPY ON ATHEROGENIC AND PROTECTIVE LIPID FACTORS: THE ACCENTUATE TRIAL
EAS Academy, Stephen Nicholls, 136703
LESSONS FROM CLINICAL TRIALS
EAS Academy, Jane Armitage, 136699
LESSONS FROM CLINICAL EXPERIENCE
EAS Academy, Urlich Laufs, 136698
ANTI-INFLAMMATORY INTERVENTIONS VERSUS INTENSIVE LDL LOWERING
EAS Academy, Francois Mach, 136702
Debate on Statin Associated Muscle Symptoms (SAMS) - A Problem for Clinicians or a Problem with Clinicians? Chair
EAS Academy, Chris Packard, 137123
LEADING THE WAY TO GENETICS AND PHARMACOGENOMICS IN THE CLINIC
EAS Academy, Teri Manolio, 136696
GWAS FOR CORONARY ARTERY DISEASE
EAS Academy, Heribert Schunkert, 136695
GENETIC PROTECTION FROM CORONARY ARTERY DISEASE: THE ROLE OF ABCG5 AND ABCG8
EAS Academy, Helen Hobbs, 136694
PANEL DISCUSSION
EAS Academy, Session Speakers, 137188
ROLE OF MICROBIOTA ON CARDIOVASCULAR DISEASE
EAS Academy, Jingyuan Fu, 136680
PLANT STEROL AND STANOLS AND CARDIOVASCULAR DISEASE. IMPACT OF ENRICHED FOODS AND CHOLESTEROL LOWERING DRUGS
EAS Academy, John M. Chapman, 136679
SUGAR INTAKE AND CARDIOVASCULAR DISEASE - SHOULD IT BE THE NEXT FIGHT TO DECREASE CVD?
EAS Academy, Jean-Pierre Despres, 136678
SHOULD SATURATED FAT BE TARGETED FOR THE PREVENTION OF CARDIOVASCULAR DISEASE?
EAS Academy, Alice H. Lichtenstein, 136677
Swedish experience from patient society
EAS Academy, Gunnar Karlsson, 118047
The lipid clinic and organization of FH, the role of different participants in the team
EAS Academy, Kjetil Retterstøl, 118046
FH in children
EAS Academy, Albert Wiegman, 118044
The role of new lipid lowering drugs
EAS Academy, Kausik Ray, 118043
Treatment of FH: Diet, statin and statin intolerance
EAS Academy, Olov Wiklund, 118042
Cascade screening introduction and experience from Czech Republic
EAS Academy, Tomas Freiberger, 118039
Cascade screening introduction and experience from Spain
EAS Academy, Pedro Mata, 118040
Diagnosis of FH: Scoring systems and Genetic diagnosis, Polygenic causes of clinical FH
EAS Academy, Joep Defesche, 118038
Genetics of FH mutation and distribution
EAS Academy, Stefano Romeo, 118037
The population burden of FH- The need to close the gap
EAS Academy, Kausik Ray, 118036
Module 5: Mendelian randomization approach to understand effect of lipoprotein in causing disease
EAS Academy, Anne Tybjaerg-Hansen, 99034
Investing in your arteries: lifetime management of CVD risk
EAS Academy, John E. Deanfield, 97705
Concluding remarks
EAS Academy, Kausik Ray, 98851
Taking a quantum leap in management strategies
EAS Academy, Seth Baum, 97693
The therapeutic backbone
EAS Academy, Claudia Stefanutti, 97692
Modernising our understanding of HoFH
EAS Academy, Jeanine Roeters van Lennep, 97691
What is the best lipid treatment target? Discussion from the diversity of current guidelines.
EAS Academy, Alberico Luigi Catapano, 97687
What is the role of the different lipoproteins in atherogenesis?
EAS Academy, Jan Borén, 97686
Imaging for estimation risk and disease regression, advancements and new techniques.
EAS Academy, Zahi Fayad, 97685
Future therapies
EAS Academy, Erik Stroes, 97682
Current status of hypolipidaemic therapies
EAS Academy, Chris Packard, 97681
Dyslipidaemias: from lifestyle to genetics
EAS Academy, Kausik Ray, 97680
Engaging with governments- how to get genetic screening into law
EAS Academy, Mario Stoll, 97676
Getting started in your region and Data collation and National governance
EAS Academy, Kausik Ray, 97674
What worked well with the Dutch Database and what we are doing differently for the HoFH database
EAS Academy, Kees Hovingh, 97672
The Ten Countries Study - What's happening in the Asia Pacific Region and synergy with the FHSC
EAS Academy, Gerald Watts, 97671
The potential and limitations of historical data- using UK as an exemplar
EAS Academy, Handrean Soran, 97670
FH Studies Collaboration Symposium and Aims and objectives of the EAS FHSC and the FHSC survey
EAS Academy, Kausik Ray, 97668
What genes can teach about the link between obesity and cardiometabolic traitan integrated approach
EAS Academy, Ruth Loos, 65108
Mendelian randomization: from genetic association to disease mechanism
EAS Academy, Anne Tybjaerg-Hansen, 65107
Genome wide association studies to find genetic determinants of cardiovascular disease
EAS Academy, Olle Melander, 65106
Discussion and data presentation on ANGPTL4
EAS Academy, Stefano Romeo, 65105
Tools to study candidate genes (2)
EAS Academy, Maria Antonella Burza, 65102
ANGPTL3 association and fasting triglycerides
EAS Academy, Stefano Romeo, 65101
Tools to study candidate gene (1)
EAS Academy, Maria Antonella Burza, 65100
Monogenic form of hypercholesterolemia
EAS Academy, Knut Erik Berge, 65097
Module 7: Genetics in cardiovascular disease
EAS Academy, EAS, 65167
Module 11: Pharmacological treatment of other dyslipidemias
EAS Academy, EAS, 65172
Epidemiological and clinical evidence in favour or against clinical utility of different procedures
EAS Academy, Dan O'Leary, 56082
Novel methods
EAS Academy, Erik Stroes, 56083
Classical and Novel Risk Factors
EAS Academy, Naveed Sattar, 56078
PCSK9 INHIBITION
EAS Academy, Bertrand Cariou, 56081
Rebuttal
EAS Academy, Luis Masana Marin, 56099
Rebuttal
EAS Academy, Kausik Ray, 56098
All statins cause diabetes? The case AGAINST the motion
EAS Academy, Luis Masana Marin, 56097
All statins cause diabetes? The case FOR the motion
EAS Academy, Kausik Ray, 56096
From nutrients to food: key features of our diet providing cardio prevention
EAS Academy, Frank Hu, 56073
Lessons from the PREDIMED trial
EAS Academy, Emilio Ros, 56074
Lessons from LOOK AHEAD
EAS Academy, Jean-Pierre Despres, 56075
Physical Activity and CVD risk
EAS Academy, Rainer Rauramaa, 56076
Monoclonal antibodies targeting PCSK9: gaining insight into their potential in clinical practice
EAS Academy, Alberico Luigi Catapano, 56778
Monoclonal antibodies targeting PCSK9: gaining insight into their potential in clinical practice
EAS Academy, Evan A. Stein, 56779
Management in Hyperlipidemia: what does the furture hold?
EAS Academy, Evan A. Stein, 56777
Hyperlipidemia management in high-risk patients: what we have and what we need
EAS Academy, John J.P. Kastelein, 56776
REGULATION OF ADIPOGENESIS
EAS Academy, Ulf Smith, 56068
Lipotoxic heart disease
EAS Academy, Ira Goldberg, 56070
Diabetic Dyslipidemia
EAS Academy, Marja-Riitta Taskinen, 56067
Review of current status for the guidelines on dyslipidemia – comparing European and US guidelines
EAS Academy, Olov Wiklund, 56063
Risk estimation and risk calculation
EAS Academy, Ian Graham, 56064
Challenges for future Guidelines
EAS Academy, Guy De Backer, 56065
Looking to the future – guidance on lipids and other targets
EAS Academy, Børge Nordestgaard, 56066
Mixed hyperlipidemia and triglycerides in current guidelines for treatment
EAS Academy, Olov Wiklund, 56061
Mechanistic bases for the origin and therapy of elevated triglycerides and mixed hyperlipidemia.
EAS Academy, Gerald Watts, 56060
Triglycerides, cholesterol and HDL in CVD – lessons from genetics
EAS Academy, Børge Nordestgaard, 56059
Role of Microbiota in Atherosclerosis
EAS Academy, Fredrik Bäckhed, 56051
Vaccination against atherosclerosis
EAS Academy, Johan Kuiper, 56053
Anitschkow Lecture
EAS Academy, John J.P. Kastelein, 56050
Tools of the trade - New treatment options in HoFH
EAS Academy, Dirk J. Blom, 56093
When to intervene - The urgency to treat
EAS Academy, Gilbert Thompson, 56092
Identifying the target - Who are we treating and to what target?
EAS Academy, Marina M. Cuchel, 56091
Diet – the corner stone of cholesterol management
EAS Academy, David Jenkins, 56043
Behaviour change is possible \'small steps – big difference\'
EAS Academy, Luis Masana Marin, 56044
Behaviour change is possible, behaviour change in practice
EAS Academy, Helena Gylling, 56045
Introducing the e-Learning tool
EAS Academy, Simon Hackett, 56046
New advances in the role of Lp(a) in atherosclerosis; Therapeutic implications
EAS Academy, Olov Wiklund, 53306
Familial hypercholesterolemia: can we do a better job? Molecular genetics: is the screening of lipid disorders useful in clinical practice?
EAS Academy, Sebastiano Calandra, 53305
New therapeutic approaches in lipidology
EAS Academy, Alberico Luigi Catapano, 53304
Update on new EAS/ESC joint European guidelines for the prevention and treatment of dyslipidemia
EAS Academy, Alberico Luigi Catapano, 53302
CV risk evaluation through algorithms
EAS Academy, Olov Wiklund, 53301
Atherosclerosis: update on the pathophysiology: role of LDL
EAS Academy, Petri Kovanen, 53299
Emerging cardiovascular therapies targeting the immune system
EAS Academy, Jan Nilsson, 34718
Circulating Cells and Cardiovascular Risk
EAS Academy, Harry Björkbacka, 34712
Exploration and modulation of regulatory T cells in atherosclerosis
EAS Academy, Hafid Ait-Oufella, 34717
Immunomodulation of atherosclerosis
EAS Academy, Daniel F.J. Ketelhuth, 34716
The role of Dendritic Cells in Atherosclerosis
EAS Academy, Clément Cochain, 34713
T cell subsets in atherosclerosis
EAS Academy, Maria Wigren, 34835
Ontogeny and atherosclerosis pathology of B lymphocytes
EAS Academy, Stephen Malin, 34711
Emerging therapeutic approaches to treat dyslipidemias
EAS Academy, Chris Packard, 31157
Lipidomics ? a novel tool for biomarker discovery
EAS Academy, Robert Gerszten, 31155
Module 12: Emerging treatments of dyslipidemia
EAS Academy, EAS, 65173
Translating new approaches to reduce LDL cholesterol into future therapies
EAS Academy, Evan A. Stein, 31569
PCSK9 inhibition, a safe and efficient strategy to lower LDL cholesterol?
EAS Academy, Gilles Lambert, 31567
LDL cholesterol and cardiovascular risk reduction - successes and challenges
EAS Academy, Lale Tokgözoglu, 31565
Pharmacological targets identified by genetic approaches
EAS Academy, Francois Cambien, 31153
Therapeutic options to induce regression of coronary atherosclerosis
EAS Academy, Steven Nissen, 31152
Micro-RNA and epigenetic control of atherogenesis
EAS Academy, Kathryn Moore, 31151
Gut-liver interaction in triglyceride rich lipoprotein metabolism
EAS Academy, Gary Lewis, 31150
Module 15: Lipids, lipoproteins and metabolism (Recommended)
EAS Academy, EAS, 65176
Clinical application & safety of plant sterols/stanols
EAS Academy, Henry Ginsberg, 31560
Normalising Dyslipidemia and Reversing Atherosclerosis in Cardiometabolic Disease: Insights from Statin Pharmacotherapy
EAS Academy, John M. Chapman, 31556
Basic science of plant sterols/stanols
EAS Academy, Jogchum Plat, 31559
Normalising Dyslipidemia and Reversing Atherosclerosis in Cardiometabolic Disease: Insights from Statin Pharmacotherapy Introduction
EAS Academy, Yasushi Saito, 31555
Emerging LDL-C-lowering therapies - Targeting clearance
EAS Academy, Michel Farnier, 31553
New and emerging LDL-C-lowering therapies - Targeting production
EAS Academy, Erik Stroes, 31552
The spectrum of difficult-to-treat hypercholesterolemic patients
EAS Academy, Christie M. Ballantyne, 31551
Prevention and treatment of plaque thrombogenicity
EAS Academy, Gilles Montalescot, 31149
Advances in visualizing the unstable plaque
EAS Academy, Filippo Crea, 31148
New insights into the role of hemodynamics in plaque instability
EAS Academy, Yiannis Chatzizisis, 31147
Biomarkers of plaque of instability
EAS Academy, Jean-Baptiste Michel, 31146
THE ANITSCHKOW LECTURE
EAS Academy, Peter Libby, 31159
EAS/ESC recommendations for the management of patients with HoFH
EAS Academy, Eric Bruckert, 31545
What are we able to achieve for our patients today?
EAS Academy, Raul D. Santos, 31544
Current treatment of dyslipidaemia in patients with the metabolic syndrome
EAS Academy, Børge Nordestgaard, 31537
Risk of diabetes development during statin treatment
EAS Academy, Naveed Sattar, 31535
Hypercholesterolemia - What can we do for high-risk patients?
EAS Academy, Kees Hovingh, 31540
Lipid metabolism and cardiovascular disease in diabetes
EAS Academy, Marja-Riitta Taskinen, 31533
Module 2: Arterial wall in atherosclerosis
EAS Academy, EAS, 65162
Module 4: Basics on lipids as risk factors
EAS Academy, EAS, 65164
Module 16: Therapy (Recommended)
EAS Academy, EAS, 65177
Future treatments
EAS Academy, Alberico Luigi Catapano, 27925
Pathophysiology of Atherosclerosis
EAS Academy, Goran Hansson, 27924
Familial hypercholesterolemia in clinical practice
EAS Academy, Kees Hovingh, 27922
Latest updates on Familial Hypercholesterolaemia
EAS Academy, EAS, 113064
Module 8: Familial dyslipidemias
EAS Academy, EAS, 65168
Diabetes, metabolic syndrome
EAS Academy, Marja-Riitta Taskinen, 27921
Imaging to detect atherosclerosis and in risk assessment
EAS Academy, Goran Bergstrom, 27920
Module 3: Risk assessment with risk algorithms and guidelines
EAS Academy, Olov Wiklund, 99032
Epidemiology. Development of cardiovascular disease in different populations
EAS Academy, Annika Rosengren, 27918
Module 2: Epidemiology. Development of cardiovascular disease in different populations
EAS Academy, Annika Rosengren, 99031
Basics in Lipoprotein Metabolism
EAS Academy, Jan Borén, 27917
Module 6: Basics in Lipoprotein Metabolism
EAS Academy, Jan Borén, 99035
Module 1: Epidemiology of ASVD
EAS Academy, Annika Rosengren, 65161
Module 3: Risk assessment and guidelines
EAS Academy, EAS, 65163
Module 5: Risk factors: Lipoprotein(a) and triglycerides
EAS Academy, EAS, 65165
Module 6: Lipids, lipoproteins and metabolism
EAS Academy, EAS, 65166
Familial hypercholesterolemia: can we do better job? Molecular Genetics: is the screening of lipid disorders useful in clinical practice?
EAS Academy, Sebastiano Calandra, 25428
Imaging of arteries: does it help to improve risk evaluation?
EAS Academy, Lale Tokgözoglu, 25427
Module 9: Imaging and Biomarkers in diagnosis of atherosclerosis
EAS Academy, EAS, 65169
New Therapeutic Approaches in Lipidology
EAS Academy, Alberico Luigi Catapano, 25426
Update on new EAS/ESC Joint European Guidelines for the Prevention and Treatment of Dyslipidemia
EAS Academy, Alberico Luigi Catapano, 25425
Update on HDL biology: structure, metabolism and function in health and disease
EAS Academy, Petri Kovanen, 25423
Atherosclerosis: update on the pathophysiology: role of LDL
EAS Academy, Petri Kovanen, 25422
Module 7: Atherosclerosis: update on the pathophysiology: role of LDL
EAS Academy, Petri Kovanen, 99036
ECONOMIC ISSUES IN CARDIOVASCULAR DISEASE: WHAT ARE THE COSTS OF PREVENTION?
EAS Academy, Giuseppe Mancia, 20874
NEW PERSPECTIVES IN HYPOLIPIDEMIC TREATMENT
EAS Academy, John J.P. Kastelein, 20875
LIFESTYLE AND NUTRITIONAL STRATEGIES IN PREVENTING CARDIOVASCULAR DISEASE
EAS Academy, Aila Rissanen, 20873
GENERAL TRENDS OF CARDIOVASCULAR DISEASE IN EUROPE AND RISK FACTORS IN SPECIAL POPULATIONS
EAS Academy, Børge Nordestgaard, 20872
Module 14: Epidemiology of ASVD (Recommended)
EAS Academy, Børge Nordestgaard, 65175
Module 13: Lifestyle and nutrition in cardiovascular prevention
EAS Academy, EAS, 65174
Pitavastatin: addressing challenges: JAPAN-ACS and CIRCLE studies
EAS Academy, Hidenori Arai, 21241
Pitavastatin for the management of dyslipidaemia and atherosclerosis
EAS Academy, José-Ramon Gonzalez -Juanatey, 21240
Managing dyslipidaemia complicated with diabetes or high cardiovascular risk: how well are we doing?
EAS Academy, John Betteridge, 21239
CAN WE ENCOURAGE OUR HYPERCHOLESTEROLEMIC PATIENTS TO TAKE PLANT STEROL ENRICHED FOODS?
EAS Academy, Eric Bruckert, 21237
ARE LIPOPROTEIN REMNANTS A REASONABLE TARGET FOR THERAPY?
EAS Academy, Henry Ginsberg, 20869
GENETICS OF ATHEROGENIC DYSLIPIDEMIAS
EAS Academy, Robert Hegele, 20868
NOVEL ANTI-ATHEROGENIC MECHANISMS OF HDL AND ABC TRANSPORTERS
EAS Academy, Alan Tall, 20867
THE MACROPHAGE LIPOPROTEIN INTERACTIONS – FOR GOOD OR FOR BAD
EAS Academy, Miranda van Eck, 20866
New treatment options in patients with severe heterozygous FH: applying antisense technology
EAS Academy, Christie M. Ballantyne, 21236
Metabolic regulation of apoB-containing lipoproteins in severe FH
EAS Academy, Gerald Watts, 21235
Risk factors in severe heterozygous FH
EAS Academy, Eric Bruckert, 21234
Improving patient management – how implementation of the latest guidelines will help
EAS Academy, Lale Tokgözoglu, 21231
Treatment challenges in patients with familial hypercholesterolaemia
EAS Academy, Marcello Arca, 21230
Further reducing cardiovascular risk – what to target?
EAS Academy, Julian Halcox, 21229
UNDERSTANDING THE VULNERABLE PLAQUE – BASIS FOR TREATMENT OPTIONS
EAS Academy, Gerard Pasterkamp, 20863
IMMUNITY IN ATHEROSCLEROSIS
EAS Academy, Goran Hansson, 20862
ENDOTHELIAL FUNCTION AND DYSFUNCTION: THE KEYS TO CORONARY AND PERIPHERAL CIRCULATION
EAS Academy, Ulf Landmesser, 20861
BUILDING A VESSEL WALL: FROM DEVELOPMENTAL BIOLOGY TO PHYSIOLOGICAL AND PATHOLOGICAL REMODELING IN ADULT LIFE
EAS Academy, Mark Majesky, 20860
Intoduction to the Anitschkow lecture
EAS Academy, John M. Chapman, 20857
A BRIEF HISTORY OF CHOLESTEROL LOWERING
EAS Academy, Terje R Pedersen, 20858
Module 1: A brief history of cholesterol lowering
EAS Academy, Terje R Pedersen, 99030
Module 10: Pharmacological treatment of hypercholesterolemia
EAS Academy, EAS, 65171
Comprehensive management of dyslipidemic patients at risk: Should we prescribe antiaggregants?
EAS Academy, Jean-Philippe Collet, 18304
New advances in the role of Lp(a) in atherosclerosis; Therapeutic implications
EAS Academy, Børge Nordestgaard, 18303
Familial hypercholesterolemia: can we do a better job? Molecular Genetics: is the screening of lipid disorders useful in clinical practice?
EAS Academy, Alain Carrié, 18302
Familial hypercholesterolemia: can we do a better job? Molecular Genetics: is the screening of lipid disorders useful in clinical practice?
EAS Academy, Eric Bruckert, 18301
New Therapeutic Approaches in Lipidology
EAS Academy, John M. Chapman, 18300
Imaging of arteries: does it help to improve risk evaluation?
EAS Academy, Lale Tokgözoglu, 18299
Update on new EAS/ESC Joint European Guidelines for the Prevention and Treatment of Dyslipidemia
EAS Academy, Olov Wiklund, 18298
CV Risk evaluation through Algorithms
EAS Academy, Eric Bruckert, 18297
Update on HDL biology: structure , metabolism and function in health and disease
EAS Academy, John M. Chapman, 18296
THE NEW EAS/ESC GUIDELINES TO TREAT DYSLIPIDEMIAS
EAS Academy, Alberico Luigi Catapano, 8236
WHAT IS A HEALTHY DIET, AS DEFINED BY THE CRITERIA OF EVIDENCE-BASED MEDICINE?
EAS Academy, Gabriele Riccardi, 8235
Module 8: What is a healthy diet, as defined by the criteria of evidence-based medicine?
EAS Academy, Gabriele Riccardi, 99038
IMMUNE MODULATION/VACCINATION TO TREAT AND PREVENT ATHEROSCLEROSIS
EAS Academy, Jan Nilsson, 8234
THE ROLE OF INFLAMMATORY BIOMARKERS IN DAILY DECISION MAKING
EAS Academy, Børge Nordestgaard, 8233
NEW IMAGING POSSIBILITIES IN ATHEROSCLEROSIS
EAS Academy, James Rudd, 8231
THE CELLULAR BIOLOGY OF PLAQUE NECROSIS
EAS Academy, Ira Tabas, 8230
PATHOLOGY OF THE VULNERABLE PLAQUE: WHAT DOES IT LOOK LIKE?
EAS Academy, Erling Falk, 8229
DIVERSITY OF HDL PARTICLES - A CHALLENGE FOR TREATMENT
EAS Academy, John M. Chapman, 8225
POST-PRANDIAL LIPID METABOLISM
EAS Academy, Stephen Young, 8227
NEW INSIGHTS INTO THE ETIOLOGY AND PATHOPHYSIOLOGY OF HEREDITARY DYSLIPIDEMIAS
EAS Academy, Helen Hobbs, 8226
THE ANITSCHKOW LECTURE: CETP INHIBITION AS A STRATEGY TO REDUCE CARDIOVASCULAR RISK
EAS Academy, Philip Barter, 8224
CLOSE
EAS Academy, Andrew A. Tonkin, 8249
HOT TOPICS IN TARGETED INTERVENTION OF CVD RISK
EAS Academy, Session Speakers, 8989
NEW OPPORTUNITIES FOR CARDIOVASCULAR DISEASE PREVENTION
EAS Academy, Stephen Nicholls, 8248
VASCULAR FUNCTION - THERAPEUTIC TARGET OR CARDIOVASCULAR RISK MARKER
EAS Academy, John Deanfield, 8253
HOT TOPICS IN THE IMPLEMENTATION OF GUIDELINES IN CLINICAL PRACTICE
EAS Academy, Session Speakers, 8988
IMPLEMENTING EFFECTIVE CVD RISK MANAGEMENT IN CLINICAL PRACTICE
EAS Academy, David A. Wood, 8247
HOT TOPICS RELATING TO THE CHALLENGES FACED IN EFFECTIVE CARDIOVASCULAR RISK MANAGEMENT
EAS Academy, Session Speakers, 8987
CHALLENGES TO EFFECTIVE CARDIOVASCULAR RISK MANAGEMENT
EAS Academy, Alberto Zambon, 8246
HDL FUNCTION AND REVERSE CHOLESTEROL TRANSPORT IN HUMANS: CAN THEY BE PROMOTED BY THERAPEUTIC INTERVENTION?
EAS Academy, Marina M. Cuchel, 8251
Module 4: The role of inflammatory biomarkers in daily decision making
EAS Academy, Børge Nordestgaard, 99033
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings